These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 31620934)

  • 41. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.
    Staaf J; Ringnér M; Vallon-Christersson J; Jönsson G; Bendahl PO; Holm K; Arason A; Gunnarsson H; Hegardt C; Agnarsson BA; Luts L; Grabau D; Fernö M; Malmström PO; Johannsson OT; Loman N; Barkardottir RB; Borg A
    J Clin Oncol; 2010 Apr; 28(11):1813-20. PubMed ID: 20231686
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
    Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
    Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women.
    Rebbeck TR; DeMichele A; Tran TV; Panossian S; Bunin GR; Troxel AB; Strom BL
    Carcinogenesis; 2009 Feb; 30(2):269-74. PubMed ID: 19028704
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fibroblast growth factor receptor 1 protein (FGFR1) as potential prognostic and predictive marker in patients with luminal B breast cancers overexpressing human epidermal receptor 2 protein (HER2).
    Amina B; Lynda AK; Sonia S; Adel B; Jelloul BH; Miloud M; Tewfik S
    Indian J Pathol Microbiol; 2021; 64(2):254-260. PubMed ID: 33851617
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Correlation Between Raf/MEK/ERK Signaling Pathway and Clinicopathological Features and Prognosis for Patients With Breast Cancer Having Axillary Lymph Node Metastasis.
    Shao GL; Wang MC; Fan XL; Zhong L; Ji SF; Sang G; Wang S
    Technol Cancer Res Treat; 2018 Jan; 17():1533034617754024. PubMed ID: 29529946
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.
    Rydén L; Jirström K; Haglund M; Stål O; Fernö M
    Breast Cancer Res Treat; 2010 Apr; 120(2):491-8. PubMed ID: 20135347
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.
    Li Y; Yang D; Yin X; Zhang X; Huang J; Wu Y; Wang M; Yi Z; Li H; Li H; Ren G
    JAMA Netw Open; 2020 Jan; 3(1):e1918160. PubMed ID: 31899528
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26-30.
    Park S; Han Y; Liu Y; Toriola AT; Peterson LL; Colditz GA; Kim SI; Cho YU; Park BW; Park Y
    Breast Cancer Res; 2019 Oct; 21(1):110. PubMed ID: 31619259
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.
    Zardavas D; Te Marvelde L; Milne RL; Fumagalli D; Fountzilas G; Kotoula V; Razis E; Papaxoinis G; Joensuu H; Moynahan ME; Hennessy BT; Bieche I; Saal LH; Stal O; Iacopetta B; Jensen JD; O'Toole S; Lopez-Knowles E; Barbaraeschi M; Noguchi S; Azim HA; Lerma E; Bachelot T; Wang Q; Perez-Tenorio G; Can de Velde CJH; Rea DW; Sabine V; Bartlett JMS; Sotiriou C; Michiels S; Loi S
    J Clin Oncol; 2018 Apr; 36(10):981-990. PubMed ID: 29470143
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.
    Tanioka M; Fan C; Parker JS; Hoadley KA; Hu Z; Li Y; Hyslop TM; Pitcher BN; Soloway MG; Spears PA; Henry LN; Tolaney S; Dang CT; Krop IE; Harris LN; Berry DA; Mardis ER; Winer EP; Hudis CA; Carey LA; Perou CM
    Clin Cancer Res; 2018 Nov; 24(21):5292-5304. PubMed ID: 30037817
    [No Abstract]   [Full Text] [Related]  

  • 51. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy.
    Strasser-Weippl K; Horick N; Smith IE; O'Shaughnessy J; Ejlertsen B; Boyle F; Buzdar AU; Fumoleau P; Gradishar W; Martin M; Moy B; Piccart-Gebhart M; Pritchard KI; Lindquist D; Rappold E; Finkelstein DM; Goss PE
    Breast Cancer Res; 2015 Apr; 17(1):56. PubMed ID: 25888246
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database.
    Roberts MC; Miller DP; Shak S; Petkov VI
    Breast Cancer Res Treat; 2017 Jun; 163(2):303-310. PubMed ID: 28243896
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Are there changes in characteristics and therapy of young patients with early-onset breast cancer in Germany over the last decade?
    Banz-Jansen C; Heinrichs A; Hedderich M; Waldmann A; Wedel B; Mebes I; Diedrich K; Rody A; Fischer D
    Arch Gynecol Obstet; 2013 Aug; 288(2):379-83. PubMed ID: 23407999
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer.
    Han J; Choi YL; Kim H; Choi JY; Lee SK; Lee JE; Choi JS; Park S; Choi JS; Kim YD; Nam SJ; Nam BH; Kwon MJ; Shin YK
    Breast Cancer Res Treat; 2017 Jul; 164(1):41-56. PubMed ID: 28409241
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lucitanib for the Treatment of HR
    Hui R; Pearson A; Cortes J; Campbell C; Poirot C; Azim HA; Fumagalli D; Lambertini M; Daly F; Arahmani A; Perez-Garcia J; Aftimos P; Bedard PL; Xuereb L; Scheepers ED; Vicente M; Goulioti T; Loibl S; Loi S; Pierrat MJ; Turner NC; Andre F; Curigliano G
    Clin Cancer Res; 2020 Jan; 26(2):354-363. PubMed ID: 31619444
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long non-coding RNA00544 serves as a potential novel predictive and prognostic marker for HR+ HER2- subtype breast cancer.
    Liu L; Chi Y; Chen J; Xue J; Deng L; Huang N; Shao J; Wu J
    Sci Rep; 2017 Sep; 7(1):12382. PubMed ID: 28959047
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
    Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
    Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study.
    Luen SJ; Asher R; Lee CK; Savas P; Kammler R; Dell'Orto P; Biasi OM; Demanse D; Hackl W; Thuerlimann B; Viale G; Di Leo A; Colleoni M; Regan MM; Loi S
    Ann Oncol; 2020 Oct; 31(10):1359-1365. PubMed ID: 32652112
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer.
    Shimizu C; Masuda N; Yoshimura K; Tsuda H; Mano M; Ando M; Tamura K; Fujiwara Y
    Jpn J Clin Oncol; 2009 Aug; 39(8):484-90. PubMed ID: 19477897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.